Literature DB >> 18058331

The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.

Jun-Sheng Wang1, D Jeffrey Newport, Zachary N Stowe, Jennifer L Donovan, Page B Pennell, C Lindsay DeVane.   

Abstract

P-glycoprotein, breast cancer resistance protein, and multidrug resistance proteins have physiological functions in placental tissue. Several antidepressants, antipsychotics, and anti-epileptic drugs have been found to be substrates of P-glycoprotein and other transporters. The extent that drugs pass through the placental barrier is likely influenced by drug transporters. The rational choice of psychoactive drugs to treat mental illness in women of child-bearing age should incorporate knowledge of both drug disposition as well as expected pharmacologic effects. This review summarizes the current data on drug transporters in the placental passage of medications, with a focus on medications used in clinical psychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058331     DOI: 10.1080/03602530701690390

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  15 in total

Review 1.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 2.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

3.  Model Placental Barrier Phenotypic Response to Fluoxetine and Sertraline: A Comparative Study.

Authors:  Navein Arumugasaamy; Alana Gudelsky; Amelia Hurley-Novatny; Peter C W Kim; John P Fisher
Journal:  Adv Healthc Mater       Date:  2019-08-13       Impact factor: 9.933

4.  Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Authors:  Dorothy Sit; James M Perel; Stephen R Wisniewski; Joseph C Helsel; James F Luther; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2011-07       Impact factor: 4.384

5.  Placental passage of antiepileptic drugs at delivery and neonatal outcomes.

Authors:  Anna M Bank; Zachary N Stowe; D Jeffrey Newport; James C Ritchie; Page B Pennell
Journal:  Epilepsia       Date:  2017-04-07       Impact factor: 5.864

Review 6.  Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome.

Authors:  Grace Ewing; Yekaterina Tatarchuk; Dina Appleby; Nadav Schwartz; Deborah Kim
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 7.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 8.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

9.  Tacrolimus placental transfer at delivery and neonatal exposure through breast milk.

Authors:  Songmao Zheng; Thomas R Easterling; Karen Hays; Jason G Umans; Menachem Miodovnik; Shannon Clark; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 10.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.